Beyond Air

XAIR

Market cap $12M

Overview Fund Activity

2.30 USD

-0.12

4.96%

At close Updated Sep 17, 12:11 PM EDT

1 day

-4.96%

5 days

0.88%

1 month

-4.17%

3 months

-59.65%

6 months

-61.86%

Year to date

-67.97%

1 year

-70.81%

5 years

-97.89%

10 years

-98.02%

About: Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Employees: 61

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0.48% less ownership

Funds ownership: 1.09% [Q1] → 0.61% (-0.48%) [Q2]

9% less funds holding

Funds holding: 43 [Q1] → 39 (-4) [Q2]

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

63% less capital invested

Capital invested by funds: $5.24M [Q1] → $1.96M (-$3.28M) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$11

378% upside

Avg. target

$11

378% upside

High target

$11

378% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital

Jason Kolbert

$11

Buy

Maintained

21 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about XAIR published over the past 30 days

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding common warrants (the “Existing Warrants”) to purchase up to an aggregate of 1,439,126 shares of the Company's common stock at a reduced exercise price of $2.21 (the closing price of the Company's shares of common stock on September 5, 2025). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.25 million, prior to deducting placement agent fees and estimated offering expenses.

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2026 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - Chief Financial Officer Steven Adam Lisi - CEO & Chairman of the Board Conference Call Participants I-Eh Jen - Laidlaw & Company (UK) Ltd., Research Division Jason Hart Wittes - ROTH Capital Partners, LLC, Research Division Jason M.

Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript

Zacks Investment Research

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $5.4 per share a year ago.

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its first fiscal quarter ended June 30, 2025 on Tuesday, August 12, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc. Effective July 15th, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the LungFit PH system and disposable NO2 Smart Filters.

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

Zacks Investment Research

Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Beyond Air (XAIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR ) Q4 2025 Earnings Conference Call June 17, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - CFO, Principal Financial Officer & Principal Accounting Officer Steven Adam Lisi - CEO & Chairman of the Board Conference Call Participants I-Eh Jen - Laidlaw & Company (UK) Ltd., Research Division Jason Hart Wittes - ROTH Capital Partners, LLC, Research Division Joseph Daniel Downing - Piper Sandler & Co., Research Division Justin Howard Walsh - JonesTrading Institutional Services, LLC, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Corey George Davis - Lifesci Advisors, LLC Operator Good afternoon, and welcome, everyone, to the Beyond Air Financial Results Call for the Fiscal Quarter and Year Ended March 31, 2025.

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

Zacks Investment Research

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.36 per share a year ago.

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™